Managing Pregnancy Reports in Pharmacovigilance: A Practical Guide

This blog features:

1. The importance of pregnancy-related reports in pharmacovigilance.
2. Best practices for tracking, assessing, and processing pregnancy reports.
3. Criteria for classifying pregnancy cases as ICSRs.
4. Parent–child/fetus reporting requirements in E2B(R3).
5. Key regulatory concepts and terminology for pregnancy reporting.

Introduction

Pregnancy-related cases are among the most sensitive and closely monitored reports in pharmacovigilance. Because the effects of medicinal products on an embryo, fetus, or breastfed infant may not become evident immediately, these cases require careful follow-up, accurate assessment, and compliance with regulatory reporting requirements.

Understanding which pregnancy reports qualify as Individual Case Safety Reports (ICSRs), how to document parent–child cases in E2B(R3), and when additional follow-up is required is essential for maintaining patient safety and regulatory compliance.

This article outlines the key principles and best practices for tracking, assessing, and processing pregnancy-related safety reports.

Tracking, Assessing, and Processing Pregnancy Reports

Pregnancy-related safety reports require careful follow-up because adverse outcomes may not be immediately apparent. Regulatory authorities expect marketing authorization holders to actively monitor these cases, collect complete outcome information, and assess potential risks to both the parent and the child.

Key Principles for Managing Pregnancy Reports

• Follow up all pregnancy exposure reports whenever possible. Prospective pregnancy reports and other cases of special interest should be actively monitored until the pregnancy outcome is known.
  
• Collect comprehensive outcome information. When a medicinal product may have exposed an embryo or fetus—whether through maternal or paternal exposure—follow-up should include pregnancy outcome, neonatal health, congenital abnormalities, and the child’s postnatal development where applicable.
  
• Consider exposure before conception. For medicines with long half-lives or active metabolites, exposure occurring before conception may still be clinically relevant when evaluating potential fetal risk.
  
• Classify abnormal pregnancy outcomes as serious. Reports involving congenital anomalies, developmental disorders, fetal death, spontaneous abortion, stillbirth, or serious suspected adverse reactions in neonates are considered serious ICSRs and should be reported according to applicable pharmacovigilance requirements.
  
• Not every pregnancy exposure is reportable as an ICSR. Pregnancy exposure reports with a normal outcome, no pregnancy outcome, or elective termination without evidence of a suspected adverse reaction are generally not submitted as ICSRs. However, these cases should still be documented and evaluated as part of ongoing safety surveillance and included in periodic safety reports when appropriate.
  
• Breastfeeding-related adverse reactions are also pregnancy-related safety cases. Suspected adverse reactions occurring in infants following exposure to medicinal products through breast milk should be reported according to standard pharmacovigilance reporting criteria.
  
• Paternal exposure requires special consideration. If the suspected medicinal product was taken only by the father but the reported event involves miscarriage, stillbirth, or early spontaneous abortion, the pregnancy case is documented using the mother as the patient, while details of the father’s exposure are recorded within the case information.

Parent–Child/Fetus Reporting in E2B(R3)

When a fetus or child experiences one or more suspected adverse reactions following exposure to a medicinal product during pregnancy, a single parent–child/fetus ICSR should be created.

In these reports:

• The child or fetus is considered the patient.
  
• Patient characteristics in the structured report refer to the child or fetus.
  
• Information about the mother or father is recorded in the parent section.
  
• If both parents were exposed to the suspected medicinal product, the structured parent information should describe the mother, while relevant information about the father should be included in the case narrative.

Important Terminology

Two pharmacovigilance terms are commonly misunderstood in pregnancy reporting:

• In spontaneous reporting, the term ‘adverse event’ is synonym to (suspected) adverse reaction and all birth defects are (suspected) ‘serious adverse reactions’.
  
• Pregnancy outcome refers to the result of the pregnancy itself (for example, live birth, spontaneous abortion, stillbirth, or congenital anomaly). This differs from the general pharmacovigilance use of outcome, which describes the result or resolution of an adverse reaction.

Conclusion

Effective management of pregnancy-related safety reports goes beyond simply documenting drug exposure. It requires continuous follow-up, thorough assessment of pregnancy outcomes, accurate classification of reportable cases, and adherence to E2B(R3) reporting standards.

By understanding how to manage maternal and paternal exposures, breastfeeding cases, and parent–child/fetus reports, pharmacovigilance professionals can ensure high-quality safety data, support regulatory compliance, and contribute to the ongoing evaluation of medicine safety for both parents and children.